NEW YORK (GenomeWeb) – Nuclea Biotechnologies today said it has inked an agreement with Clinical Reference Laboratory to validate three of Nuclea's tests.

As part of the deal, CRL will initially validate Nuclea's Oncogene Science 159 gene-based prostate cancer monitoring test. Nuclea obtained the test when it acquired Wilex, the wholly owned subsidiary of Wilex AG, in September.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.